Botox 200 unit vials
Ended Awarded
- Contract number
- SPE2DB26FY18X
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,234
Award facts
- Contract value 100% obligated
- $3,234.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $3,234.25 to DMS Pharmaceutical Group Inc. for BOTOX 200 unit vials on November 5, 2025, with an ultimate completion date of November 28, 2025. This firm fixed-price delivery order was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, comprising a 30-month base period with three additional 30-month option periods. The PPV-G GEN V program is a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors that supply comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FY18X?
SPE2DB26FY18X was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DB26FY18X worth?
The government has obligated $3,234 on SPE2DB26FY18X.
Is contract SPE2DB26FY18X an order under another contract?
Yes. SPE2DB26FY18X is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB26FY18X competed?
The extent of competition for SPE2DB26FY18X was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award